| Scrip Code | 544172 |
|---|---|
| NSE Symbol | INDGN |
| MSEI Symbol | NOTLISTED |
| ISIN | INE065X01017 |
| Name of company | Indegene Limited |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2025 |
| Date of end of financial year | 31-03-2026 |
| Date of board meeting when results were approved | 29-04-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 21-04-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | Fourth quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | Audited |
| Segment Reporting | Single segment |
| Description of single segment | Where financial results contain both consolidated financial results and standalone financial results of the parent, segment information is required to be presented only in the consolidated financial results. Accordingly, segment information has been presented in the consolidated financial results. |
| Start date and time of board meeting | 29-04-2026 17:30:00 |
| End date and time of board meeting | 29-04-2026 19:10:00 |
| Whether cash flow statement is applicable on company | Yes |
| Type of cash flow statement | Cash Flow Indirect |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Whether the company has any related party? | Yes |
| Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? | Yes |
| (I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public | NA |
| (II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. | NA |
| Whether the company is a high value debt listed entity according to regulation 15 (1A)? | No |
| (a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication? | |
| (b) If answer to above question is No, please explain the reason for not complying. | |
| Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? | Yes |
| Latest Date on which RPT policy is updated | 29-04-2026 |
| Indicate Company website link for updated RPT policy of the Company | https://ir.indegene.com/en/investor-relations/corporate-governance/ |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No |
| No. of times funds raised during the quarter | |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| No external loans and debt securities held by Company | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Unaudited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 36,820.00 | 1,22,060.00 | |
| Other income | 610.00 | 7,830.00 | |
| Total income | 37,430.00 | 1,29,890.00 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 0.00 | 0.00 |
| (b) | Purchases of stock-in-trade | 0.00 | 0.00 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 0.00 | 0.00 |
| (d) | Employee benefit expense | 21,340.00 | 79,520.00 |
| (e) | Finance costs | 310.00 | 870.00 |
| (f) | Depreciation, depletion and amortisation expense | 1,090.00 | 3,630.00 |
| (f) | Other Expenses | ||
| 1 | Other expenses | 5,170.00 | 17,730.00 |
| Total other expenses | 5,170.00 | 17,730.00 | |
| Total expenses | 27,910.00 | 1,01,750.00 | |
| 3 | Total profit before exceptional items and tax | 9,520.00 | 28,140.00 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 9,520.00 | 28,140.00 |
| 6 | Tax expense | ||
| 7 | Current tax | 2,600.00 | 7,070.00 |
| 8 | Deferred tax | (290.00) | (120.00) |
| 9 | Total tax expenses | 2,310.00 | 6,950.00 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 7,210.00 | 21,190.00 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 7,210.00 | 21,190.00 |
| 17 | Other comprehensive income net of taxes | (590.00) | (280.00) |
| 18 | Total Comprehensive Income for the period | 6,620.00 | 20,910.00 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 4,810.00 | 4,810.00 | |
| Face value of equity share capital | 2 | 2 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | 2,03,240.00 | |
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 3 | 8.83 | |
| Diluted earnings (loss) per share from continuing operations | 2.98 | 8.78 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 3 | 8.83 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 2.98 | 8.78 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Earnings per share is not annualised for quarter ended 1 The above Standalone Financial Results of the Indegene Limited the Company have been prepared in accordance with Indian Accounting Standards Ind AS 34 Interim Financial Reporting recognition and measurement principles of Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act 2013 as amended read with the relevant rules issued there under and in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 the Regulations Due to rounding off the numbers presented throughout may not add up precisely to the totals Caret symbol in the financial information denote amounts less than INR 50 lakh 2 The above Standalone Financial Results have been reviewed by the Audit Committee held on 28 April 2026 and approved by the Board of Directors at its meeting held on 29 April 2026 The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of full financial year and published unaudited year to date figures upto the end of the third quarter of the current financial year which were subject to limited review 3 The Standalone Financial Results for the quarter and year ended 31 March 2026 are available on the National Stock Exchange of India Limited URL www nseindia com the BSE Limited website URL www bseindia com and on the Company s website URL www indegene com investor relations 4 During the year ended 31 March 2025 the Company had completed Initial Public Offer IPO of 40766550 equity shares of face value of INR 2 each at an issue price of INR 452 per share Issue price of INR 422 including a share premium of INR 420 per share for employee quota towards fresh issue comprising fresh issue of 16833818 shares aggregating to INR 7600 and offer for sale of 23932732 shares by selling shareholders aggregating to INR 10818 The equity shares of the Company are listed in National Stock Exchange of India Limited NSE and BSE Limited BSE on 13 May 2024 The Company has received an amount of INR 7246 net of Company s share of IPO expenses of INR 354 retained in the Public Offer Account to the extent unpaid from the proceeds of the fresh issue Out of the Company s shares of IPO expenses INR 319 has been adjusted to securities premium The utilization of IPO proceeds of INR 7246 Repayment or prepayment of indebtedness of one of the material subsidiary ILSL Holdings Inc The amount to be utilised as per the offer document is 3950 The amount utilized up to 31 March 2026 is 3950 The amount unutilized as of 31 March 2026 is nil Funding the capital expenditure requirements of the Company and one of the material subsidiary Indegene Inc The amount to be utilised as per the offer document is 644 The amount utilized up to 31 March 2026 is 577 The amount unutilized as of 31 March 2026 is 67 Technology cybersecurity and cloud infrastructure related cost The amount to be utilised as per the offer document is 350 The amount utilized up to 31 March 2026 is 253 The amount unutilized as of 31 March 2026 is 97 General corporate purposes and inorganic growth The amount to be utilised as per the offer document is 2302 The amount utilized up to 31 March 2026 is 2294 The amount unutilized as of 31 March 2026 is 8 The total amount to be utilised as per the offer document is 7246 The total amount utilized up to 31 March 2026 is 7074 The total amount unutilized as of 31 March 2026 is 172 1 Pursuant to the Special Resolution passed at the Shareholders Meeting held on 12 August 2025 the Company has revised the objects as per offer document As per the revised objects an amount of INR 37 is adjusted from funding capital expenditure requirements towards repayment of indebtedness of ILSL Holdings Inc for the difference arising due to exchange rate fluctuation as on the date of offer document and as on the date of repayment Further an amount of INR 350 is reclassified from funding capital expenditure requirement towards utilization for services including cloud infrastructure and security services productivity tools cybersecurity and support services availed by the Company and Indegene Inc Further the Board of Directors of the Company has approved the transfer of unutilized IPO expense towards funding capital expenditure requirement by way of Board Resolution passed on 29 January 2026 The unutilized amount of INR 2 has been transferred to the net IPO proceeds thereby increasing it from INR 7244 to INR 7246 and earmarked for funding capital expenditure requirements at the Company s office premises 2 During the year ended 31 March 2025 the Company has repaid loan of USD 47 Million INR 3950 outstanding in the books of ILSL Holdings Inc material subsidiary in line with Object 1 of the offer document The amount of INR 37 utilised over and above the maximum amount specified as per the original amount as per offer document of INR 3913 was due to exchange rate fluctuation as on the date of offer document and as on the date of payment The Special Resolution passed on 12 August 2025 revises the object amount to adjust this difference Out of the net proceeds which were unutilised as at 31 March 2026 INR 151 31 March 2025 INR 980 are temporarily invested in fixed deposits INR 19 31 March 2025 INR 41 is held in the Company s monitoring account while the balance amount of INR 2 31 March 2025 Nil is held in the public offer account |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | Year ended (dd-mm-yyyy) | ||
|---|---|---|---|
| Date of start of reporting period | 01-04-2025 | ||
| Date of end of reporting period | 31-03-2026 | ||
| Whether results are audited or unaudited | Audited | ||
| Nature of report standalone or consolidated | Standalone | ||
| Assets | |||
| 1 | Non-current assets | ||
| Property, plant and equipment | 11,260.00 | ||
| Capital work-in-progress | 1,180.00 | ||
| Investment property | 0.00 | ||
| Goodwill | 0.00 | ||
| Other intangible assets | 0.00 | ||
| Intangible assets under development | 0.00 | ||
| Biological assets other than bearer plants | 0.00 | ||
| Investments accounted for using equity method | 0.00 | ||
| Non-current financial assets | |||
| Non-current investments | 61,660.00 | ||
| Trade receivables, non-current | 0.00 | ||
| Loans, non-current | 35,500.00 | ||
| Other non-current financial assets | |||
| 1 | Other financial assets | 6,930.00 | |
| Total of other non-current financial assets | 6,930.00 | ||
| Total non-current financial assets | 1,04,090.00 | ||
| Deferred tax assets (net) | 2,380.00 | ||
| Other non-current assets | |||
| 1 | Non-current tax assets (net) | 1,720.00 | |
| 2 | Other non-current assets | 70.00 | |
| Total of other non-current assets | 1,790.00 | ||
| Total non-current assets | 1,20,700.00 | ||
| 2 | Current assets | ||
| Inventories | 0.00 | ||
| Current financial asset | |||
| Current investments | 70,160.00 | ||
| Trade receivables, current | 28,840.00 | ||
| Cash and cash equivalents | 4,850.00 | ||
| Bank balance other than cash and cash equivalents | 8,110.00 | ||
| Loans, current | 4,430.00 | ||
| Other current financial assets | |||
| Total of other current financial assets | 2,910.00 | ||
| Total current financial assets | 1,19,300.00 | ||
| Current tax assets (net) | 0.00 | ||
| Other current assets | |||
| 1 | Other current assets | 8,190.00 | |
| Total of other current assets | 8,190.00 | ||
| Total current assets | 1,27,490.00 | ||
| 3 | Non-current assets classified as held for sale | 0.00 | |
| 4 | Regulatory deferral account debit balances and related deferred tax Assets | 0.00 | |
| Total assets | 2,48,190.00 | ||
| Equity and liabilities | |||
| 1 | Equity | ||
| Equity attributable to owners of parent | |||
| Equity share capital | 4,810.00 | ||
| Other equity | 2,03,240.00 | ||
| Total equity attributable to owners of parent | 2,08,050.00 | ||
| Non controlling interest | |||
| Total equity | 2,08,050.00 | ||
| 2 | Liabilities | ||
| Non-current liabilities | |||
| Non-current financial liabilities | |||
| Borrowings, non-current | 0.00 | ||
| Trade payables, non-current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 0.00 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 0.00 | ||
| Total Trade payable | 0.00 | ||
| Other non-current financial liabilities | |||
| 1 | Lease liabilities | 4,800.00 | |
| 2 | Other financial liabilities | 1,390.00 | |
| Total of other non-current financial liabilities | 6,190.00 | ||
| Total non-current financial liabilities | 6,190.00 | ||
| Provisions, non-current | 6,570.00 | ||
| Deferred tax liabilities (net) | 0.00 | ||
| Deferred government grants, Non-current | 0.00 | ||
| Other non-current liabilities | |||
| Total of other non-current liabilities | |||
| Total non-current liabilities | 12,760.00 | ||
| Current liabilities | |||
| Current financial liabilities | |||
| Borrowings, current | 0.00 | ||
| Trade payables, current | |||
| (A) Total outstanding dues of micro enterprises and small enterprises | 260.00 | ||
| (B) Total outstanding dues of creditors other than micro enterprises and small enterprises | 3,000.00 | ||
| Total Trade payable | 3,260.00 | ||
| Other current financial liabilities | |||
| 1 | Lease liabilities | 2,180.00 | |
| 2 | Other financial liabilities | 10,780.00 | |
| Total of other current financial liabilities | 12,960.00 | ||
| Total current financial liabilities | 16,220.00 | ||
| Other current liabilities | 2,720.00 | ||
| 1 | Other current liabilities | 2,720.00 | |
| Total of other current liabilities | 2,720.00 | ||
| Provisions, current | 5,340.00 | ||
| Current tax liabilities (Net) | 3,100.00 | ||
| Deferred government grants, Current | 0.00 | ||
| Total current liabilities | 27,380.00 | ||
| 3 | Liabilities directly associated with assets in disposal group classified as held for sale | 0.00 | |
| 4 | Regulatory deferral account credit balances and related deferred tax liability | 0.00 | |
| Total liabilities | 40,140.00 | ||
| Total equity and liabilites | 2,48,190.00 | ||
| Disclosure of notes on assets and liabilities | Textual Information(1) | ||
| Textual Information(1) | 6 On 21 November 2025 the Government of India notified provisions of the Code on Wages 2019 the Industrial Relations Code 2020 the Code on Social Security 2020 and the Occupational Safety Health and Working Conditions Code 2020 Labour Codes which consolidate twenty nine existing labour laws into a unified framework governing employee benefits during employment and post employment The Labour Codes amongst other things introduces changes including a uniform definition of wages and enhanced benefits relating to leave The Company has considered restructured compensation of its employees with effect from 01 April 2026 and assessed the impact of the changes consistent with the Labour Codes draft rules FAQs and legal opinion The Company based on the evaluation of the labour code has concluded that these changes do not have any material impact on the Company s Financial Statements In case of any further clarification from the Government on other aspects of the New Labour Codes the Company will evaluate and account for differential impact if any in subsequent periods on the Financial Statements 7 During the year ended 31 March 2026 613772 options have been granted under Employee Restricted Stock Unit plan 2020 RSU 2020 318251 options have been granted under Employee Stock Option Plan 2020 ESOP 2020 and 56462 options have been granted under Company Share Option Plan 2022 CSOP 2022 to the eligible employee of the Company 670418 options under RSU 2020 plan 215192 options under ESOP 2020 plan and 7782 options under ESOP 2020 plan have been exercised during the year 8 The Company publishes this Standalone Financial Results along with the Consolidated Financial Results In accordance with Ind AS 108 Operating Segments the Company has disclosed the segment information in the Consolidated Financial Results 9 Contingencies During the year the Company received a draft transfer pricing order dated 18 March 2026 pertaining to Assessment Year 2023 24 issued by the Transfer Pricing Officer under the provisions of the Income tax Act 1961 proposing adjustments to the Companys returned income in respect of international transactions with associated enterprises The proposed transfer pricing adjustment in the draft order aggregates to INR 1 114 the amount of tax demand will be as per the final order which is not received as on date The Company has exercised its option to seek resolution of the proposed adjustment through the Mutual Agreement Procedure MAP in accordance with the applicable tax treaty provisions between India and the relevant treaty jurisdiction s The MAP application has been filed within the prescribed timelines Based on management s assessment supported by external tax advice and considering the merits of the case including the Company s transfer pricing documentation economic analyses and relevant judicial precedents management believes that the matter is effectively contestable and that it is not probable that an outflow of resources will be required to settle the obligation Accordingly no provision has been recognised in the financial statements as at the reporting date and the proposed exposure has been disclosed as a contingent liability pending resolution under the MAP process 10 The Board of Directors in its meeting on 29 April 2026 have proposed a final dividend of INR 2 point 25 per equity shares for the financial year ended 31 March 2026 The proposal is subject to the approval of shareholders at the ensuing Annual General Meeting and if approved would result in a cash outflow of approximately INR 542 Notes to Assets and Liabilites a Property plant and equipment includes Right of use assets of INR 673 b Trade receivables current consists Billed Revenue INR 2834 and Unbilled revenue of INR 50 |
|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-01-2026 | 01-04-2025 | |||||
| Date of end of reporting period | 31-03-2026 | 31-03-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Audited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | Textual Information(2) | ||||||
| Textual Information(2) | I Cash flows from Operating Activities 1 Other adjustments for non-cash items includes a Reversals of provision for diminution in value of loans and interest INR negative 3 b Expected credit loss provision on trade receivables and advances INR negative 7 c Gain on termination of lease INR negative 9 2 Cash flows from Investing Activities A Other Inflow Outflows of cash includes a Purchase of investments accounted using FVTPL INR negative 4440 b Proceeds from redemption of investments INR 2757 c Investments in fixed deposits INR negative 3669 d Redemption or maturity of fixed deposit INR 3617 3 Cash flows from Financing Activities Proceeds from issuing shares is net of share issue expenses |
|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-01-2026 | 01-04-2025 |
| B | Date of end of reporting period | 31-03-2026 | 31-03-2026 |
| C | Whether results are audited or unaudited | Unaudited | Audited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Remeasurement of defined benefit obligation | (10.00) | 410.00 |
| Total Amount of items that will not be reclassified to profit and loss | (10.00) | 410.00 | |
| 2 | Income tax relating to items that will not be reclassified to profit or loss | (10.00) | 100.00 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Fair value gain/(loss) arising on hedging instruments during the year | (790.00) | (790.00) |
| Total Amount of items that will be reclassified to profit and loss | (790.00) | (790.00) | |
| 4 | Income tax relating to items that will be reclassified to profit or loss | (200.00) | (200.00) |
| 5 | Total Other comprehensive income | (590.00) | (280.00) |
| Particulars | Year ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|
| A | Date of start of reporting period | 01-04-2025 | ||||
| B | Date of end of reporting period | 31-03-2026 | ||||
| C | Whether results are audited or unaudited | Audited | ||||
| D | Nature of report standalone or consolidated | Standalone | ||||
| Statement of cash flows | ||||||
| Cash flows from used in operating activities | ||||||
| Profit before tax | 28,140.00 | |||||
| Adjustments for reconcile profit (loss) | ||||||
| Adjustments for finance costs | 790.00 | |||||
| Adjustments for decrease (increase) in inventories | 0.00 | |||||
| Adjustments for decrease (increase) in trade receivables, current | 13,960.00 | |||||
| Adjustments for decrease (increase) in trade receivables, non-current | 0.00 | |||||
| Adjustments for decrease (increase) in other current assets | (1,740.00) | |||||
| Adjustments for decrease (increase) in other non-current assets | 0.00 | |||||
| Adjustments for other financial assets, non-current | 0.00 | |||||
| Adjustments for other financial assets, current | 0.00 | |||||
| Adjustments for other bank balances | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, current | 0.00 | |||||
| Adjustments for increase (decrease) in trade payables, non-current | 0.00 | |||||
| Adjustments for increase (decrease) in other current liabilities | (780.00) | |||||
| Adjustments for increase (decrease) in other non-current liabilities | 0.00 | |||||
| Adjustments for depreciation and amortisation expense | 3,630.00 | |||||
| Adjustments for impairment loss reversal of impairment loss recognised in profit or loss | 0.00 | |||||
| Adjustments for provisions, current | 1,350.00 | |||||
| Adjustments for provisions, non-current | 0.00 | |||||
| Adjustments for other financial liabilities, current | 0.00 | |||||
| Adjustments for other financial liabilities, non-current | 0.00 | |||||
| Adjustments for unrealised foreign exchange losses gains | 790.00 | |||||
| Adjustments for dividend income | 0.00 | |||||
| Adjustments for interest income | 4,440.00 | |||||
| Adjustments for share-based payments | 840.00 | |||||
| Adjustments for fair value losses (gains) | 0.00 | |||||
| Adjustments for undistributed profits of associates | 0.00 | |||||
| Other adjustments for which cash effects are investing or financing cash flow | (3,000.00) | |||||
| Other adjustments to reconcile profit (loss) | 0.00 | |||||
| Other adjustments for non-cash items | (190.00) | |||||
| Share of profit and loss from partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Total adjustments for reconcile profit (loss) | 11,210.00 | |||||
| Net cash flows from (used in) operations | 39,350.00 | |||||
| Dividends received | 0.00 | |||||
| Interest paid | 0.00 | |||||
| Interest received | 0.00 | |||||
| Income taxes paid (refund) | 4,790.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) operating activities | 34,560.00 | |||||
| Cash flows from used in investing activities | ||||||
| Cash flows from losing control of subsidiaries or other businesses | 0.00 | |||||
| Cash flows used in obtaining control of subsidiaries or other businesses | 0.00 | |||||
| Other cash receipts from sales of equity or debt instruments of other entities | 0.00 | |||||
| Other cash payments to acquire equity or debt instruments of other entities | 14,530.00 | |||||
| Other cash receipts from sales of interests in joint ventures | 0.00 | |||||
| Other cash payments to acquire interests in joint ventures | 0.00 | |||||
| Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Cash payment for investment in partnership firm or association of persons or limited liability partnerships | 0.00 | |||||
| Proceeds from sales of property, plant and equipment | 0.00 | |||||
| Purchase of property, plant and equipment | 4,410.00 | |||||
| Proceeds from sales of investment property | 0.00 | |||||
| Purchase of investment property | 0.00 | |||||
| Proceeds from sales of intangible assets | 0.00 | |||||
| Purchase of intangible assets | 0.00 | |||||
| Proceeds from sales of intangible assets under development | 0.00 | |||||
| Purchase of intangible assets under development | 0.00 | |||||
| Proceeds from sales of goodwill | 0.00 | |||||
| Purchase of goodwill | 0.00 | |||||
| Proceeds from biological assets other than bearer plants | 0.00 | |||||
| Purchase of biological assets other than bearer plants | 0.00 | |||||
| Proceeds from government grants | 0.00 | |||||
| Proceeds from sales of other long-term assets | 0.00 | |||||
| Purchase of other long-term assets | 0.00 | |||||
| Cash advances and loans made to other parties | 0.00 | |||||
| Cash receipts from repayment of advances and loans made to other parties | 0.00 | |||||
| Cash payments for future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Cash receipts from future contracts, forward contracts, option contracts and swap contracts | 0.00 | |||||
| Dividends received | 0.00 | |||||
| Interest received | 4,970.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | (13,240.00) | |||||
| Net cash flows from (used in) investing activities | (27,210.00) | |||||
| Cash flows from used in financing activities | ||||||
| Proceeds from changes in ownership interests in subsidiaries | 0.00 | |||||
| Payments from changes in ownership interests in subsidiaries | 0.00 | |||||
| Proceeds from issuing shares | 530.00 | |||||
| Proceeds from issuing other equity instruments | 0.00 | |||||
| Payments to acquire or redeem entity's shares | 0.00 | |||||
| Payments of other equity instruments | 0.00 | |||||
| Proceeds from exercise of stock options | 0.00 | |||||
| Proceeds from issuing debentures notes bonds etc | 0.00 | |||||
| Proceeds from borrowings | 0.00 | |||||
| Repayments of borrowings | 0.00 | |||||
| Payments of lease liabilities | 1,990.00 | |||||
| Dividends paid | 4,800.00 | |||||
| Interest paid | 0.00 | |||||
| Income taxes paid (refund) | 0.00 | |||||
| Other inflows (outflows) of cash | 0.00 | |||||
| Net cash flows from (used in) financing activities | (6,260.00) | |||||
| Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes | 1,090.00 | |||||
| Effect of exchange rate changes on cash and cash equivalents | ||||||
| Effect of exchange rate changes on cash and cash equivalents | 240.00 | |||||
| Net increase (decrease) in cash and cash equivalents | 1,330.00 | |||||
| Cash and cash equivalents cash flow statement at beginning of period | 3,520.00 | |||||
| Cash and cash equivalents cash flow statement at end of period | 4,850.00 | |||||
| Whether results are audited or unaudited | Audited |
|---|---|
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | Deloitte Haskins & Sells | Yes | 30-04-2028 | ||
|---|---|---|---|---|---|
Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) |
| Sr No. | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. | ||||||||||||||||||||||||
| Details of the party (listed entity/subsidiary) entering into the transaction | Details of the counterparty | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | Details of the loans, inter-corporate deposits, advances or investments | Notes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | Opening balance | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ intercorporate deposit/ investment ) | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | ||||||||||
| 1 | Indegene Limited | Cult Health LLC | Step Subsidiary | Sale of goods or services | 301.00 | Approved | 210.00 | 130.00 | 50.00 | ||||||||||||||||
| 2 | Indegene Limited | DT Associates Research and Consulting Services Limited | Step Subsidiary | Sale of goods or services | 774.00 | Approved | 310.00 | 210.00 | 280.00 | ||||||||||||||||
| 3 | Indegene Limited | Indegene FarEast Pte. Ltd. | Step Subsidiary | Sale of goods or services | 68.80 | Approved | 20.00 | 0.00 | 20.00 | ||||||||||||||||
| 4 | Indegene Limited | Indegene Healthcare Canada, Inc. | Step Subsidiary | Sale of goods or services | 86.00 | Approved | 0.00 | 0.00 | 0.00 | ||||||||||||||||
| 5 | Indegene Limited | Indegene Ireland Limited | Subsidiary | Sale of goods or services | 86.00 | Approved | 20.00 | 0.00 | 20.00 | ||||||||||||||||
| 6 | Indegene Limited | Indegene Japan LLC | Step Subsidiary | Sale of goods or services | 107.50 | Approved | 40.00 | 10.00 | 10.00 | ||||||||||||||||
| 7 | Indegene Limited | Indegene Lifesystems Consulting (Shanghai) Co. Ltd. | Step Subsidiary | Sale of goods or services | 451.50 | Approved | 140.00 | 130.00 | 150.00 | ||||||||||||||||
| 8 | Indegene Limited | Indegene, Inc. | Step Subsidiary | Sale of goods or services | 1,07,500.00 | Approved | 57,190.00 | 43,380.00 | 24,880.00 | ||||||||||||||||
| 9 | Indegene Limited | Trilogy Writing & Consulting GmbH | Step Subsidiary | Sale of goods or services | 172.00 | Approved | 60.00 | 0.00 | 10.00 | ||||||||||||||||
| 10 | Indegene Limited | Trilogy Writing & Consulting Inc | Step Subsidiary | Sale of goods or services | 86.00 | Approved | 20.00 | 0.00 | 10.00 | ||||||||||||||||
| 11 | Indegene Limited | Trilogy Writing & Consulting Limited | Step Subsidiary | Sale of goods or services | 86.00 | Approved | 0.00 | 0.00 | 0.00 | ||||||||||||||||
| 12 | Indegene Limited | Trilogy Writing & Consulting ULC | Step Subsidiary | Sale of goods or services | 86.00 | Approved | 0.00 | 0.00 | 0.00 | ||||||||||||||||
| 13 | Indegene, Inc. | Cult Health LLC | Fellow Subisidary | Sale of goods or services | Not Applicable | 90.00 | 20.00 | 20.00 | |||||||||||||||||
| 14 | Indegene, Inc. | DT Associates Research and Consulting Services Inc | Fellow Subisidary | Sale of goods or services | Not Applicable | 320.00 | 320.00 | 480.00 | |||||||||||||||||
| 15 | Indegene, Inc. | DT Associates Research and Consulting Services Limited | Fellow Subisidary | Sale of goods or services | Not Applicable | 60.00 | 310.00 | 30.00 | |||||||||||||||||
| 16 | Indegene, Inc. | Indegene Ireland Limited | Fellow Subisidary | Sale of goods or services | Not Applicable | 10.00 | 0.00 | 0.00 | |||||||||||||||||
| 17 | Biopharm Communications, LLC | Addressable Health LLC | Fellow Subisidary | Sale of goods or services | Not Applicable | 570.00 | 0.00 | 430.00 | |||||||||||||||||
| 18 | Biopharm Communications, LLC | Indegene, Inc. | Parent Company | Sale of goods or services | Not Applicable | 290.00 | 0.00 | 0.00 | |||||||||||||||||
| 19 | Cult Health LLC | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 2,660.00 | 1,010.00 | 870.00 | |||||||||||||||||
| 20 | DT Associates Research and Consulting Services Inc | DT Associates Research and Consulting Services Limited | Fellow Subisidary | Sale of goods or services | Not Applicable | 340.00 | 750.00 | 1,140.00 | |||||||||||||||||
| 21 | DT Associates Research and Consulting Services Inc | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 220.00 | 70.00 | (930.00) | |||||||||||||||||
| 22 | DT Associates Research and Consulting Services Limited | Indegene Healthcare UK Ltd | Fellow Subisidary | Sale of goods or services | Not Applicable | 20.00 | 0.00 | 0.00 | |||||||||||||||||
| 23 | DT Associates Research and Consulting Services Limited | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 2,700.00 | 2,170.00 | 600.00 | |||||||||||||||||
| 24 | Indegene Europe LLC | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 650.00 | 390.00 | 140.00 | |||||||||||||||||
| 25 | Indegene FarEast Pte. Ltd. | Indegene Japan LLC | Fellow Subisidary | Sale of goods or services | Not Applicable | 30.00 | 20.00 | 0.00 | |||||||||||||||||
| 26 | Indegene FarEast Pte. Ltd. | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 210.00 | 20.00 | 30.00 | |||||||||||||||||
| 27 | Indegene Healthcare Canada, Inc. | Indegene, Inc. | Parent Company | Sale of goods or services | Not Applicable | 1,110.00 | 0.00 | 1,820.00 | |||||||||||||||||
| 28 | Indegene Healthcare Canada, Inc. | Trilogy Writing & Consulting GmbH | Fellow Subisidary | Sale of goods or services | Not Applicable | 220.00 | 0.00 | 860.00 | |||||||||||||||||
| 29 | Indegene Healthcare Canada, Inc. | Trilogy Writing & Consulting Inc | Fellow Subisidary | Sale of goods or services | Not Applicable | 130.00 | 0.00 | 10.00 | |||||||||||||||||
| 30 | Indegene Healthcare Germany GmbH | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 1,820.00 | 280.00 | 270.00 | |||||||||||||||||
| 31 | Indegene Healthcare UK Ltd | Indegene Limited | Ultimate Parent Company | Sale of goods or services | Not Applicable | 490.00 | 0.00 | 90.00 | |||||||||||||||||
| 32 | Indegene Healthcare UK Ltd | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 4,050.00 | 630.00 | 620.00 | |||||||||||||||||
| 33 | Indegene Ireland Limited | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 530.00 | 60.00 | 130.00 | |||||||||||||||||
| 34 | Indegene Japan | DT Associates Research and Consulting Services Limited | Fellow Subisidary | Sale of goods or services | Not Applicable | 10.00 | 0.00 | 0.00 | |||||||||||||||||
| 35 | Indegene Japan | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 240.00 | 0.00 | 0.00 | |||||||||||||||||
| 36 | Indegene Lifesystems Consulting (Shanghai) Co. Ltd. | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 690.00 | 0.00 | 0.00 | |||||||||||||||||
| 37 | Indegene Spain SL | DT Associates Research and Consulting Services Limited | Fellow Subisidary | Sale of goods or services | Not Applicable | 80.00 | 0.00 | 40.00 | |||||||||||||||||
| 38 | Indegene Spain SL | Indegene Limited | Ultimate Parent Company | Sale of goods or services | Not Applicable | 10.00 | 0.00 | 10.00 | |||||||||||||||||
| 39 | Indegene Spain SL | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 130.00 | 0.00 | 40.00 | |||||||||||||||||
| 40 | MJL Advertising Limited | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 140.00 | 0.00 | 70.00 | |||||||||||||||||
| 41 | Services Indegene Aptilon, Inc. | Indegene, Inc. | Parent Company | Sale of goods or services | Not Applicable | 950.00 | 1,670.00 | 0.00 | |||||||||||||||||
| 42 | Trilogy Writing & Consulting GmbH | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 50.00 | 10.00 | 30.00 | |||||||||||||||||
| 43 | Trilogy Writing & Consulting GmbH | Trilogy Writing & Consulting Inc | Subsidiary | Sale of goods or services | Not Applicable | 3,390.00 | 2,390.00 | 6,070.00 | |||||||||||||||||
| 44 | Trilogy Writing & Consulting Inc | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 30.00 | 0.00 | 0.00 | |||||||||||||||||
| 45 | Trilogy Writing & Consulting Inc | Trilogy Writing & Consulting GmbH | Parent Company | Sale of goods or services | Not Applicable | 3,040.00 | 4,860.00 | 8,370.00 | |||||||||||||||||
| 46 | Trilogy Writing & Consulting Limited | Trilogy Writing & Consulting GmbH | Fellow Subisidary | Sale of goods or services | Not Applicable | 740.00 | (810.00) | (850.00) | |||||||||||||||||
| 47 | Trilogy Writing & Consulting Limited | Trilogy Writing & Consulting Inc | Fellow Subisidary | Sale of goods or services | Not Applicable | 980.00 | 920.00 | 1,980.00 | |||||||||||||||||
| 48 | Trilogy Writing & Consulting ULC | Trilogy Writing & Consulting GmbH | Fellow Subisidary | Sale of goods or services | Not Applicable | 600.00 | 0.00 | 0.00 | |||||||||||||||||
| 49 | Trilogy Writing & Consulting ULC | Trilogy Writing & Consulting Inc | Fellow Subisidary | Sale of goods or services | Not Applicable | (20.00) | 500.00 | 0.00 | |||||||||||||||||
| 50 | Warn & Co Limited | Indegene, Inc. | Fellow Subisidary | Sale of goods or services | Not Applicable | 120.00 | 0.00 | 30.00 | |||||||||||||||||
| 51 | Indegene Limited | Cult Health LLC | Step Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 70.00 | 0.00 | 20.00 | ||||||||||||||||
| 52 | Indegene Limited | DT Associates Research and Consulting Services Limited | Step Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | (50.00) | 1,250.00 | 1,250.00 | ||||||||||||||||
| 53 | Indegene Limited | Indegene FarEast Pte. Ltd. | Step Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 10.00 | 0.00 | 0.00 | ||||||||||||||||
| 54 | Indegene Limited | Indegene Healthcare Germany GmbH | Step Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 10.00 | 0.00 | 0.00 | ||||||||||||||||
| 55 | Indegene Limited | Indegene Healthcare UK Ltd | Step Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 230.00 | 30.00 | 30.00 | ||||||||||||||||
| 56 | Indegene Limited | Indegene, Inc. | Step Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 880.00 | 120.00 | 320.00 | ||||||||||||||||
| 57 | Indegene Limited | Trilogy Writing & Consulting GmbH | Step Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 20.00 | 0.00 | 20.00 | ||||||||||||||||
| 58 | Indegene Limited | Trilogy Writing & Consulting Limited | Step Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 20.00 | 0.00 | 20.00 | ||||||||||||||||
| 59 | Indegene, Inc. | Addressable Health LLC | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 30.00 | 0.00 | 30.00 | ||||||||||||||||
| 60 | Indegene, Inc. | Biopharm Communications, LLC | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 250.00 | 0.00 | 30.00 | ||||||||||||||||
| 61 | Indegene, Inc. | Cult Health LLC | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 710.00 | 110.00 | 130.00 | ||||||||||||||||
| 62 | Indegene, Inc. | DT Associates Research and Consulting Services Limited | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 0.00 | 20.00 | 20.00 | ||||||||||||||||
| 63 | Indegene, Inc. | Indegene Lifesystems Consulting (Shanghai) Co. Ltd. | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 30.00 | 1,350.00 | 1,460.00 | ||||||||||||||||
| 64 | Indegene, Inc. | Indegene Limited | Ultimate Parent Company | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 20.00 | 0.00 | 20.00 | ||||||||||||||||
| 65 | Indegene, Inc. | MJL Advertising Limited | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 10.00 | 0.00 | 10.00 | ||||||||||||||||
| 66 | Indegene, Inc. | Trilogy Writing & Consulting Inc | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 350.00 | 0.00 | 210.00 | ||||||||||||||||
| 67 | Biopharm Communications, LLC | Addressable Health LLC | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 360.00 | 0.00 | 0.00 | ||||||||||||||||
| 68 | Cult Health LLC | DT Associates Research and Consulting Services Limited | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 30.00 | 0.00 | 0.00 | ||||||||||||||||
| 69 | Cult Health LLC | Indegene, Inc. | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 10.00 | 100.00 | (290.00) | ||||||||||||||||
| 70 | Cult Health LLC | MJL Advertising Limited | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 10.00 | 0.00 | 0.00 | ||||||||||||||||
| 71 | DT Associates Research and Consulting Services Inc | DT Associates Research and Consulting Services Limited | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 0.00 | 10.00 | 10.00 | ||||||||||||||||
| 72 | DT Associates Research and Consulting Services Inc | Indegene, Inc. | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 0.00 | 10.00 | 10.00 | ||||||||||||||||
| 73 | DT Associates Research and Consulting Services Limited | Indegene, Inc. | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 120.00 | 300.00 | 440.00 | ||||||||||||||||
| 74 | IL SL Holdings Inc. USA | Biopharm Communications, LLC | Step Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 140.00 | 0.00 | 0.00 | ||||||||||||||||
| 75 | IL SL Holdings Inc. USA | Indegene, Inc. | Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 100.00 | 0.00 | 0.00 | ||||||||||||||||
| 76 | Indegene Healthcare Canada, Inc. | Indegene, Inc. | Parent Company | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 40.00 | 0.00 | 40.00 | ||||||||||||||||
| 77 | Indegene Healthcare UK Ltd | DT Associates Research and Consulting Services Limited | Subsidiary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 230.00 | 40.00 | 40.00 | ||||||||||||||||
| 78 | Indegene Ireland Limited | Indegene, Inc. | Fellow Subisidary | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 60.00 | 0.00 | 0.00 | ||||||||||||||||
| 79 | Services Indegene Aptilon, Inc. | Indegene, Inc. | Parent Company | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 0.00 | 20.00 | 0.00 | ||||||||||||||||
| 80 | Trilogy Writing & Consulting GmbH | Indegene Limited | Ultimate Parent Company | Any other transaction | Expenses paid on behalf of subsidiary | Not Applicable | 10.00 | 0.00 | 10.00 | ||||||||||||||||
| 81 | Indegene, Inc. | Indegene Lifesystems Consulting (Shanghai) Co. Ltd. | Fellow Subisidary | Any other transaction | Advance Given | Not Applicable | 110.00 | 390.00 | 500.00 | ||||||||||||||||
| 82 | Indegene, Inc. | ILSL Holdings, Inc. | Parent Company | Any other transaction | Advance Given | Not Applicable | 13,950.00 | 1,19,610.00 | 1,33,560.00 | ||||||||||||||||
| 83 | Indegene, Inc. | DT Associates Research and Consulting Services Limited | Fellow Subisidary | Any other transaction | Advance Given | Not Applicable | (2,050.00) | 3,000.00 | 950.00 | ||||||||||||||||
| 84 | Indegene, Inc. | Indegene Healthcare Mexico S DE RL DE CV | Fellow Subisidary | Any other transaction | Advance Given | Not Applicable | 20.00 | 0.00 | 20.00 | ||||||||||||||||
| 85 | Indegene Healthcare UK Ltd | Indegene, Inc. | Fellow Subisidary | Any other transaction | Advance Given | Not Applicable | 440.00 | 60.00 | 500.00 | ||||||||||||||||
| 86 | Indegene Ireland Limited | Indegene Spain SL | Subsidiary | Any other transaction | Advance Given | Not Applicable | 60.00 | 50.00 | 110.00 | ||||||||||||||||
| 87 | Indegene Healthcare UK Ltd | DT Associates Research and Consulting Services Limited | Subsidiary | Any other transaction | Advance Given | Not Applicable | 370.00 | 0.00 | 370.00 | ||||||||||||||||
| 88 | Indegene Limited | ILSL Holdings, Inc. | Subsidiary | Interest received | 3,870.00 | Approved | 1,790.00 | 890.00 | 930.00 | ||||||||||||||||
| 89 | Indegene Limited | Indegene Lifesystems Consulting (Shanghai) Co. Ltd. | Step Subsidiary | Interest received | 451.50 | Approved | 10.00 | 20.00 | 30.00 | ||||||||||||||||
| 90 | Indegene Limited | ILSL Holdings, Inc. | Subsidiary | Loan | 3,870.00 | Approved | 2,150.00 | 37,720.00 | 39,870.00 | Loan | 9.0400 | 5 years | Unsecured | Repayment/prepayment of the term loan from bank | Textual Information(1) | ||||||||||
| 91 | Indegene Limited | Indegene Lifesystems Consulting (Shanghai) Co. Ltd. | Step Subsidiary | Loan | Not Applicable | 0.00 | 70.00 | 70.00 | Loan | 8.00 | 5 and 10 years | Unsecured | Business needs | ||||||||||||
| 92 | Trilogy Writing & Consulting GmbH | Trilogy Writing & Consulting Limited | Fellow Subisidary | Loan | Not Applicable | 0.00 | 650.00 | 680.00 | Loan | 1.2500 | 20 years | Unsecured | Business needs | ||||||||||||
| 93 | Indegene Limited | Indegene Ireland Limited | Subsidiary | Any other transaction | Investment in subisidary | Not Applicable | 14,530.00 | 26,000.00 | 40,540.00 | ||||||||||||||||
| 94 | Indegene Limited | Dr. Ashish Gupta | Non- executive Independent Director | Any other transaction | Commission | 100.00 | Approved by Board | 60.00 | 50.00 | 0.00 | |||||||||||||||
| 95 | Indegene Limited | Mr. Jairaj Manohar Purandare | Non- executive Independent Director | Any other transaction | Commission | 50.00 | Approved by Board | 30.00 | 20.00 | 0.00 | |||||||||||||||
| 96 | Indegene Limited | Mr. Pravin Udhyavara Bhadya Rao | Non- executive Independent Director | Any other transaction | Commission | 50.00 | Approved by Board | 30.00 | 20.00 | 0.00 | |||||||||||||||
| 97 | Indegene Limited | Mr. Krishnamurthy Venugopala Tenneti | Non- executive Independent Director | Any other transaction | Commission | 50.00 | Approved by Board | 30.00 | 20.00 | 0.00 | |||||||||||||||
| 98 | Indegene Limited | Dr. Georgia Nikolakopoulou Papathomas | Non- executive Independent Director | Any other transaction | Commission | 100.00 | Approved by Board | 60.00 | 50.00 | 0.00 | |||||||||||||||
| 99 | Indegene Limited | Jill DeSimone | Non- executive Independent Director | Any other transaction | Commission | 100.00 | Approved by Board | 30.00 | 0.00 | 0.00 | |||||||||||||||
| 100 | Indegene Limited | Neeraj Bharadwaj | Non- executive Independent Director | Any other transaction | Commission | 100.00 | Approved by Board | 30.00 | 0.00 | 0.00 | |||||||||||||||
| 101 | Indegene Limited | Manish Gupta | Chief Executive Officer and Executive Director | Remuneration | 812.50 | Approved by Nomination and Remuneration Committee | 150.00 | 0.00 | 0.00 | ||||||||||||||||
| 102 | Indegene Limited | Dr. Sanjay S Parikh | Executive Director | Remuneration | 500.00 | Approved by Nomination and Remuneration Committee | 100.00 | 0.00 | 0.00 | ||||||||||||||||
| 103 | Indegene, Inc. | Dr. Rajesh B Nair | Non- executive Director | Remuneration | 255.60 | Approved by Nomination and Remuneration Committee | 140.00 | 0.00 | 0.00 | ||||||||||||||||
| 104 | Indegene Limited | Ms. Srishti Kaushik | Company Secretary | Remuneration | 78.10 | Approved by Nomination and Remuneration Committee | 30.00 | 0.00 | 0.00 | ||||||||||||||||
| 105 | Indegene Limited | Suhas Prabhu | Chief Financial Officer | Remuneration | 500.00 | Approved by Nomination and Remuneration Committee | 160.00 | 0.00 | 0.00 | ||||||||||||||||
| 106 | ILSL Holdings, Inc. | Indegene Healthcare UK Ltd | Fellow Subisidary | Any other transaction | Sale of investment | Not Applicable | 2,480.00 | 0.00 | 0.00 | ||||||||||||||||
| 107 | Trilogy Writing and Consulting GMBH | Indegene, Inc. | Fellow Subisidary | Any other transaction | Sale of investment | Not Applicable | 360.00 | 0.00 | 0.00 | ||||||||||||||||
| 108 | Trilogy Writing and Consulting GMBH | Indegene Healthcare UK Ltd | Fellow Subisidary | Any other transaction | Sale of investment | Not Applicable | 870.00 | 0.00 | 0.00 | ||||||||||||||||
| Total value of transaction during the reporting period | 1,25,350.00 | ||||||||||||||||||||||||
| Textual Information(1) | Movement in on account of change in foreign exchange rate and Repayment of Loan |